Evidence map›Paper›PMID 34132574›Full record

ArticleJournal of virology2021

Antibody-Based Inhibition of Pathogenic New World Hemorrhagic Fever Mammarenaviruses by Steric Occlusion of the Human Transferrin Receptor 1 Apical Domain.

Sol Ferrero, Maria D Flores, Connor Short, Cecilia A Vazquez, Lars E Clark, James Ziegenbein, Samantha Zink, Daniel Fuentes, Cristian Payes, María V Batto and 6 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Sol Ferrero *Laboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.
Maria D Flores *Department of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA.
Connor ShortDepartment of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA.
Cecilia A VazquezLaboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), IQUIBICEN, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-UBA, Ciudad Universitaria, Buenos Aires, Argentina.
Lars E ClarkDepartment of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
James ZiegenbeinDepartment of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA.
Samantha ZinkDepartment of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA.
Daniel FuentesDepartment of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA.
Cristian PayesLaboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.
María V BattoLaboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.
Michael CollazoDepartment of Biological Chemistry and Department of Chemistry and Biochemistry, University of California Los Angeles, Howard Hughes Medical Institute, UCLA-DOE Institute for Genomics and Proteomics, Los Angeles, California, USA.
Cybele C GarcíaLaboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), IQUIBICEN, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-UBA, Ciudad Universitaria, Buenos Aires, Argentina.
Jonathan AbrahamDepartment of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
Sandra M CordoLaboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), IQUIBICEN, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-UBA, Ciudad Universitaria, Buenos Aires, Argentina.
Jose A RodriguezDepartment of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California Los Angeles, Los Angeles, California, USA.
Gustavo HelgueraLaboratory of Pharmaceutical Biotechnology, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of California, Los Angeles · USBrigham and Women's Hospital · USHarvard University · USHoward Hughes Medical Institute · US

Funding

User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Frank V Murphy · 2018 to 2026
$34.2M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
TRD4: Design and Engineering of MicroED hardware for nanocrystallization and time resolved studiesP41GM136508 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EISENBERG, DAVID · 2020 to 2024
$7.6M
Micro Electron Diffraction of Toxic and/or Infectious Macromolecular NanoassembliesR35GM128867 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Jose Alfonso Rodriguez · 2018 to 2026
$3.1M
Development of a broad spectrum therapeutic against New World hemorrhagic feversR21AI135851 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RODRIGUEZ, JOSE ALFONSO · 2018 to 2019
$429k
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)HHS | NIH | National Institute of General Medical Sciences (NIGMS) 5R21AI135851-02MINCyT | ANPCyT | Fondo para la Investigación Científica y Tecnológica (FonCyT) IP-COVID19-929MINCyT | ANPCyT | Fondo para la Investigación Científica y Tecnológica (FonCyT) PICT 2018-3954National Science Foundation (NSF) DMR-1548924NIAID NIH HHS R21 AI135851NIGMS NIH HHS P30 GM124165NIGMS NIH HHS P41 GM136508NIGMS NIH HHS R35 GM128867NIGMS NIH HHS T32 GM007185U.S. Department of Energy (DOE) DE-FC02-02ER63421
6 · The paper itself

Abstract

Pathogenic clade B New World mammarenaviruses (NWM) can cause Argentine, Venezuelan, Brazilian, and Bolivian hemorrhagic fevers. Sequence variability among NWM glycoproteins (GP) poses a challenge to the development of broadly neutralizing therapeutics against the entire clade of viruses. However, blockade of their shared binding site on the apical domain of human transferrin receptor 1 (hTfR1/CD71) presents an opportunity for the development of effective and broadly neutralizing therapeutics. Here, we demonstrate that the murine monoclonal antibody OKT9, which targets the apical domain of hTfR1, can sterically block cellular entry by viral particles presenting clade B NWM glycoproteins (GP1-GP2). OKT9 blockade is also effective against viral particles pseudotyped with glycoproteins of a recently identified pathogenic Sabia-like virus. With nanomolar affinity for hTfR1, the OKT9 antigen binding fragment (OKT9-Fab) sterically blocks clade B NWM-GP1s and reduces infectivity of an attenuated strain of Junin virus. Binding of OKT9 to the hTfR1 ectodomain in its soluble, dimeric state produces stable assemblies that are observable by negative-stain electron microscopy. A model of the OKT9-sTfR1 complex, informed by the known crystallographic structure of sTfR1 and a newly determined structure of the OKT9 antigen binding fragment (Fab), suggests that OKT9 and the Machupo virus GP1 share a binding site on the hTfR1 apical domain. The structural basis for this interaction presents a framework for the design and development of high-affinity, broadly acting agents targeting clade B NWMs.

Indexed as

A549 CellsAmino Acid SequenceAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralArenaviruses, New WorldGlycoproteinsHemorrhagic Fever, AmericanHumansProtein Structure, TertiaryReceptors, TransferrinAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralGlycoproteinsReceptors, Transferrinantiviral agentselectron microscopyJuninMachupomammarenavirusmonoclonal antibodiesSabiá-liketransferrin receptorX-ray crystallography

Identifiers

PMID34132574
PMCPMC8354235
OpenAlexW3168563468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.